Cargando…
Real-World Outcomes Among Patients with Cystic Fibrosis Treated with Ivacaftor: 2012–2016 Experience
INTRODUCTION: In this long-term, postapproval, observational study, data from the US Cystic Fibrosis Foundation Patient Registry and the UK Cystic Fibrosis Registry were used to evaluate the impact of ivacaftor treatment on cystic fibrosis (CF) by comparing outcomes in ivacaftor-treated patients wit...
Autores principales: | Higgins, Mark, Volkova, Nataliya, Moy, Kristin, Marshall, Bruce C., Bilton, Diana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229122/ https://www.ncbi.nlm.nih.gov/pubmed/32304091 http://dx.doi.org/10.1007/s41030-020-00115-8 |
Ejemplares similares
-
Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor
por: Bessonova, Leona, et al.
Publicado: (2018) -
Registry-based study in people with cystic fibrosis and an R117H variant treated with ivacaftor
por: Higgins, Mark, et al.
Publicado: (2023) -
Ivacaftor: Five‐year outcomes in the West of Scotland cystic fibrosis population
por: Al‐Din, Yasmin, et al.
Publicado: (2023) -
Tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2019) -
Lumacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)